Search form

Search form

BioFire Diagnostics has received an additional $20 million investment from Athyrium Opportunities Fund, increasing the amount of funding from the group to $45 million. The company said it will use the new funding to further commercialize its FilmArray molecular diagnostic platform. The platform's FilmArray Respiratory Panel can detect 17 viral and three bacterial targets. The company said it is also seeing progress with the product's other panels, including one for sepsis.

Related Summaries

BioFire Diagnostics, the molecular biology affiliate of bioMerieux, has obtained 510(k) clearance and a Clinical Laboratory Improvement Amendments waiver for its FilmArray Respiratory Panel EZ, a test that detects three bacterial pathogens and 11 viruses using nasopharyngeal swabs. The test, which operates on the FilmArray platform for about an hour and requires two minutes of hands-on time, is expected to be launched in the US next month.

The FDA has given BioMerieux unit BioFire Diagnostics clearance for use of its high-throughput FilmArray Torch platform with the FilmArray blood culture identification panel, gastrointestinal panel and meningitis/encephalitis panel. The CE-marked PCR system was previously cleared for use with the FilmArray respiratory panel.

BioFire Diagnostics has secured FDA clearance for its FilmArray Blood Culture Identification, or BCID, panel, which the company says can detect more than 100 pathogens linked to sepsis. The device takes just about an hour to spot a pathogen in nine of 10 positive blood cultures and is meant to give hospitals a faster way to detect bloodstream infections.

BioFire Diagnostics has received an additional $20 million investment from Athyrium Opportunities Fund, increasing the amount of funding from the group to $45 million. The company said it will use the new funding to further commercialize its FilmArray molecular diagnostic platform. The platform's FilmArray Respiratory Panel can detect 17 viral and three bacterial targets. The company said it is also seeing progress with the product's other panels, including one for sepsis.

BioFire Diagnostics has obtained $25 million from Athyrium Opportunities Fund to hasten commercialization of its FilmArray diagnostic platform, which can detect three bacterial and 17 viral targets. BioFire is developing panels for blood culture tests and other assays.